Health Canada is about to authorize the antiviral drug against COVID-19 Paxlovid developed by the laboratory Pfizer, confirmed The duty.
The information was first reported on the airwaves of the morning show of 98.5 FM Since you have to get up and at Radio-Canada.
Ottawa also announced a technical information session on therapeutic treatments for COVID-19 on Monday at 11 a.m.
Last week, Canada’s Chief Public Health Officer, Dr. Theresa Tam, reported that initial clinical trials with Paxlovid reduced the serious effects of COVID-19, such as hospitalizations.
She also added that Canada was lucky to have access to this drug, but that it would be restricted at first due to global supply limitations. Theresa Tam also argued that Public Health would seek expert advice to determine how the drug would initially be distributed.
Last December, the drug had been approved in the United States by the American Medicines Agency (FDA).
It was said at the time that the pill reduced hospitalizations and deaths by almost 90% in people at risk when taken in the first days after the onset of symptoms. These data were based on clinical trials involving more than 2200 people.
Further details will follow.
With information from Marie Vastel and Boris Proulx
To see in video